25 September 2020 - Jyseleca demonstrated durable efficacy combined with a consistent safety profile in rheumatoid arthritis through 52 weeks in Phase 3 clinical development program.

Gilead Sciences and Galapagos today announced that the European Commission has granted marketing authorization for Jyseleca (filgotinib 200 mg and 100 mg tablets), a once-daily, oral, JAK1 inhibitor for the treatment of adults with moderate to severe active rheumatoid arthritis who have responded inadequately to, or are intolerant to, one or more disease modifying anti-rheumatic drugs. 

Jyseleca may be used as monotherapy or in combination with methotrexate.

Read Gilead press release